Type(s) of chemotherapy-Escalated BEACOPP Posts on Medivizor
Navigation Menu

Type(s) of chemotherapy-Escalated BEACOPP Posts on Medivizor

Do ACE inhibitors help with anthracycline-induced cardiotoxicity in leukemia and lymphoma?

Posted by on Dec 6, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate if enalapril influences anthracycline-induced cardiotoxicity in children with leukemia and lymphoma. This study concluded that enalapril has a role in reducing anthracycline-induced cardiotoxicity in these patients. Some background Anthracyclines are a class of chemotherapy drugs that can be used for...

Read More

Does anti-PD1 therapy change the effectiveness of chemotherapy in unresponsive Hodgkin lymphoma?

Posted by on Jun 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the effects of chemotherapy alone or chemotherapy plus anti-PD1 therapy in patients with relapsing/refractory (RR) Hodgkin's Lymphoma. The main finding was that anti-PD1 treatment enhances the effectiveness of chemotherapy in these patients. Some background Stem cell transplant (SCT) and...

Read More

Does liposomal doxorubicin improve heart side effects in lymphoma patients compared to conventional doxorubicin?

Does liposomal doxorubicin improve heart side effects in lymphoma patients compared to conventional doxorubicin?

Posted by on Feb 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the impact of liposomal doxorubicin (Adriamycin) on cardiac side effects in lymphoma patients compared to conventional doxorubicin. The study suggested that liposomal doxorubicin can reduce cardiac effects and still be an effective therapy, particularly for patients at high risk for anthracycline-induced...

Read More

Risk of heart failure in survivors of Hodgkin lymphoma treated with anthracyclines and/or chest radiation

Risk of heart failure in survivors of Hodgkin lymphoma treated with anthracyclines and/or chest radiation

Posted by on Feb 23, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors looked at the relationship between heart failure and different treatments for Hodgkin Lymphoma. This study concluded that the risk of heart failure increased with increasing radiation doses and the use of chemotherapy containing anthracyclines (such as doxorubicin). Some background Hodgkin lymphoma (HL) has high 10-year...

Read More

Reducing time between salvage chemotherapy cycles in relapsed or refractory Hodgkin lymphoma

Posted by on Jan 20, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined whether a faster course of salvage chemotherapy reduced tumor volume in patients with relapsed or refractory Hodgkin lymphoma. The authors concluded that shorter intervals between SC cycles was safe and effective. Some background Hodgkin lymphoma is considered to be a highly curable form of...

Read More